Next Article in Journal
Essential Oils from Different Plant Parts of Eucalyptus cinerea F. Muell. ex Benth. (Myrtaceae) as a Source of 1,8-Cineole and Their Bioactivities
Next Article in Special Issue
Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches
Previous Article in Journal
Real-Time Translocation and Function of PKCβII Isoform in Response to Nociceptive Signaling via the TRPV1 Pain Receptor
Previous Article in Special Issue
Echinacea—A Source of Potent Antivirals for Respiratory Virus Infections
Open AccessArticle

Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments

Influenza Research Institute, 15/17 prof. Popova str., St. Petersburg 197376, Russia
ValentaPharm, Ltd., 18 block 2, Gen. Dorokhova str., Moscow 119530, Russia
Author to whom correspondence should be addressed.
Pharmaceuticals 2011, 4(12), 1518-1534;
Received: 31 August 2011 / Revised: 16 November 2011 / Accepted: 18 November 2011 / Published: 25 November 2011
(This article belongs to the Special Issue Antivirals)
Respiratory viral infections constitute the most frequent reason for medical consultations in the World. They can be associated with a wide range of clinical manifestations ranging from self-limited upper respiratory tract infections to more devastating conditions such as pneumonia. In particular, in serious cases influenza A leads to pneumonia, which is particularly fatal in patients with cardiopulmonary diseases, obesity, young children and the elderly. In the present study, we show a protective effect of the low-molecular weight compound Ingavirin (6-[2-(1H-imidazol-4-yl)ethylamino]-5-oxohexanoic acid) against influenza A (H1N1) virus, human parainfluenza virus and human adenovirus infections in animals. Mortality, weight loss, infectious titer of the virus in tissues and tissue morphology were monitored in the experimental groups of animals. The protective action of Ingavirin was observed as a reduction of infectious titer of the virus in the lung tissue, prolongation of the life of the infected animals, normalization of weight dynamics throughout the course of the disease, lowering of mortality of treated animals compared to a placebo control and normalization of tissue structure. In case of influenza virus infection, the protective activity of Ingavirin was similar to that of the reference compound Tamiflu. Based on the results obtained, Ingavirin should be considered as an important part of anti-viral prophylaxis and therapy. View Full-Text
Keywords: influenza; parainfluenza virus; adenovirus; pandemic; Ingavirin; antiviral; animal model influenza; parainfluenza virus; adenovirus; pandemic; Ingavirin; antiviral; animal model
MDPI and ACS Style

Zarubaev, V.V.; Garshinina, A.V.; Kalinina, N.A.; Shtro, A.A.; Belyaevskaya, S.V.; Slita, A.V.; Nebolsin, V.E.; Kiselev, O.I. Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments. Pharmaceuticals 2011, 4, 1518-1534.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop